Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo

Other

Hayashibara Co., Ltd.

Tsunetaka Ohta

Masashi Kurimoto

Kanso Iwaki

Tadanori Mayumi

Shinsaku Nakagawa

Yasuo Tsutsumi

Harumi Ariyasu

Shigeharu Fukuda

Tetsuya Mori

Keizo Kohno

Kozo Yamamoto

Toshio Ariyasu

Emiko Ohashi

Yoshiaki Yanai

Masahi Kurimoto

Chie Ushio

Hiroyoshi Tahata

Noboru Izumi

Akira Harashima

Tohru Kayano

Kazue Takayama

The present invention has an object to provide a mouthwash composition for preventing and/or treating periodontal diseases safely and effectively. The present invention solves the above object by providing a mouthwash composition for preventing and/or treating periodontal diseases, characterized in that it comprises, as an effective ingredient(s), one or more members selected from the group consisting of adenosine N1-oxide, 3'-glucosyladenosine N1-oxide, 5&#x2032;-glucosyladenosine N1-oxide, 5&#x2032;-adenosine diphosphate N1-oxide, and 5&#x2032;-adenosine triphosphate N1-oxide but does not contain any saccharide assimilable by periodontal disease bacteria.

Mouthwash composition for preventing and/or treating periodontal diseases

The present invention has the first object to provide a monoclonal antibody specific to interferon &#x3b1; subtype &#x3b1;8 (IFN&#x3b1;8) and its mutant proteins, the second object to provide a hybridoma capable of producing the monoclonal antibody, the third object to provide a method for detecting the IFN&#x3b1;8 and its mutant proteins by the monoclonal antibody, the fourth object to provide a method for purifying the IFN&#x3b1;8 and its mutant proteins by the monoclonal antibody, and the fifth object to provide a therapeutic agent for treating diseases whose onsets or exacerbation are related with IFN&#x3b1;8. The present invention solves the above objects by providing a monoclonal antibody specific to IFN&#x3b1;8 and its mutant proteins, a hybridoma capable of producing the monoclonal antibody, a method for detecting the IFN&#x3b1;8 and its mutant proteins by immunoreaction using the monoclonal antibody, a method for purifying the IFN&#x3b1;8 and its mutant proteins using the monoclonal antibody, and a therapeutic agent for treating diseases whose onsets or exacerbation are related with IFN&#x3b1;8, which contains the monoclonal antibody as an effective ingredient.

Monoclonal antibodies specific for human interferon-alpha subtype alpha 8

The present invention has an object to provide a tumor necrosis factor mutant protein, particularly, a tumor necrosis factor mutant protein specific to TNF-R1 or TNF-R2; tumor necrosis factor inhibitor; or tumor necrosis factor preparation containing it as an effective ingredient, and the object is solved by providing a tumor necrosis factor mutant protein where one or more amino acid residues selected from the group consisting of 29th, 31st, 32nd, 145th, 146th and 147th, or the group consisting of 84th to 89th from the N-terminal of the amino acid sequence of SEQ ID NO:1 is/are replaced with other amino acid residue(s); a tumor necrosis factor inhibitor; and a tumor necrosis factor preparation containing it as an effective ingredient.

Human tumor necrosis factor-&#x3b1; mutants

Tumor necrosis factor-alpha mutants

Disclosed are a DNA which encodes murine trehalase, a polypeptide expressed by the DNA, and a transgenic- and knockout- animals which have been genetically engineered with the DNA. The DNA comprises a part or the whole of the nucleotide sequence of SEQ ID NO:1.

DNA which encodes trehalase and uses thereof

An agent which contains, as effective ingredients, interferon-.gamma. and a biologically active substance with either or both activities of promoting production of platelets and leukocytes. A small amount of the agent effectively promotes platelet and/or leukocyte production in mammals including humans without causing side effects.

Agent for promoting the platelet and the leukocyte productions

Disclosed is a novel protein which has a molecular weight of 45,000.+-.5,000 and pI 5.7.+-.0.5 and exhibits cancer metastasis-inhibitory activity. The protein can be prepared by culturing human cells, animal cells and microorganisms capable of producing the protein in a nutrient culture medium while stimulating them with an inducer such as Bacille Calmette-Guerin and lipopolysaccharide.

Process for preparing a protein which inhibits metastasis of cancer

Insertion of IFN-alpha promoters in recombinant DNAs improves their expression efficiencies for useful polypeptides. Expression of such a recombinant DNA in host cells of mammalian origin is artificially controllable by the presence and absence of external stimuli using IFN-alpha inducers. Thus, transformants with such a recombinant DNA readily increase to a maximized cell density with causing neither damages nor extinction due to polypeptides they produce, and subsequent exposure to IFN-alpha inducers allows the proliferated cells to efficiently produce polypeptides with significant glycosylations.

Recombinant DNA and transformant containing the same

Disclosed is a novel protein which has a molecular weight of 45,000.+-.5,000 and pI 5.7.+-.0.5 and exhibits cancer metastasis-inhibitory activity. The protein can be prepared by culturing human cells, animal cells and microorganisms capable of producing the protein in a nutrient culture medium while stimulating them with an inducer such as Bacille Calmette-Gu erin and lipopolysaccharide.

DNA encoding protein possessing metastasis-inhibitory activity

Protein possessing metastasis-inhibitory activity

Growing community of inventors

Okayama, Japan

Tsunetaka Ohta